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Boston, MAA B S T R A C TObjectives: Cost-utility analyses (CUAs) have been published widely
over the years to measure the value of health care interventions. We
investigated the growth and characteristics of CUAs in the peer-
reviewed English-language literature through 2012. Methods: We
analyzed data from the Tufts Medical Center Cost-Effectiveness
Analysis (CEA) Registry, a database containing more than 3700
English-language CUAs published through 2012. We summarized
various study characteristics (e.g., intervention type, funding source,
and journal of publication) and methodological practices (e.g., use of
probabilistic sensitivity analysis) over three time periods: 1990 to 1999,
2000 to 2009, and 2010 to 2012. We also examined CUAs by country,
region, and the degree to which diseases studied correlate with
disease burden. Results: The number of published CUAs rose from
34 per year from 1990 to 1999 to 431 per year from 2010 to 2012. The
proportion of studies focused on the United States declined from 61%
during 1990 to 1999 to 35% during 2010 to 2012 (P o 0.0001). Althoughee front matter Copyright & 2015, International S
r Inc.
.1016/j.jval.2014.12.002
n@tuftsmedicalcenter.org.
ndence to: Peter J. Neumann, 800 Washington Strestill small compared with CUAs in higher income countries, the
number of CUAs focused on lower and middle-income countries has
risen sharply. A large fraction of studies pertain to pharmaceuticals
(46% during 2010–2012). In recent years, most studies included
probabilistic sensitivity analysis (67% during 2010–2012). Journals
publishing CUAs vary widely in the percentage of their studies funded
by drug companies. Some conditions, such as injuries, have high
burden but few CUAs. Conclusions: Our review reveals considerable
growth and some change in the cost-utility literature in recent years.
The data suggest growing interest in cost-utility methodology, partic-
ularly in non-Western countries.
Keywords: cost-effectiveness analysis, cost-utility analysis, quality-
adjusted life-year, review.
Copyright & 2015, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
For several decades, cost-effectiveness analyses (CEAs) have
occupied an important part of the health policy landscape. As
health costs have risen, policymakers have naturally become
more interested in measuring the value of services and in ﬁnding
ways to deliver care more efﬁciently. CEAs can inform these
efforts by quantifying the incremental costs and health beneﬁts
of interventions compared with alternative uses of resources.
Although explicit use of CEA has varied across countries, payers,
and other perspectives, the vast amount of cost-effectiveness
information available inﬂuences perceptions about value. Thus, it
is useful to scrutinize the growing cost-effectiveness literature to
understand the characteristics of published studies and how they
have changed over time.
Cost-utility analysis (CUA) is a special case of CEA in which
health effects are measured in terms of quality-adjusted life-
years (QALYs) gained. Such analyses have been recommended by
consensus groups, because they capture in a single measure
gains from both prolongation and quality of life, because they
incorporate the value or preferences people place on different
health outcomes, and because they provide a convenient meansof comparing analyses of diverse interventions and conditions
[1,2]. This article analyzes the cost-utility literature through 2012,
focusing on studies that measure outcomes in terms of cost per
QALYs. This study updates and expands our earlier analysis,
which covered the ﬁeld through 2001 and found a growing
number of CUA publications across diverse applications and
targeting the United States, Canada, Australia, and Western
European countries [3].Methods
The Tufts Medical Center Cost-Effectiveness Analysis Registry
We analyzed data from the Tufts Medical Center Cost-
Effectiveness Analysis Registry (www.cearegistry.org), a database
containing detailed information on more than 3700 English-
language CUAs published in peer-reviewed journals through
2012 (updates are provided regularly). The search protocols and
inclusion criteria for the registry have been detailed elsewhere
[3,4]. Brieﬂy, analysts searched MEDLINE for English-language
publications using the keywords “QALY,” “quality adjusted,” andociety for Pharmacoeconomics and Outcomes Research (ISPOR).
et, Box #63, Boston, MA 02111.
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identify articles that contain an original CUA while excluding
systematic reviews, editorials, non–English-language articles,
and methodological articles. Note that our review focused on
CUAs; we did not consider CEAs in the form of cost per life-years
gained, nor did we examine studies that used disability-adjusted
life-years as the measure of beneﬁt.
Each article was reviewed using standardized data collection
forms and an accompanying manual to ensure completeness,
clarity, and uniformity. Two reviewers with expertise in decision
analysis and cost-effectiveness independently reviewed each
article and convened for a consensus audit to resolve discrep-
ancies. The forms were based on “checklists” developed by the
Panel on Cost-Effectiveness in Health and Medicine [5,6], and on
other established guidelines and recommendations for collecting
information from the cost-effectiveness literature [7–9]. We
collected data onmore than 40 variables, including descriptive detail
on the intervention, comparator, target population, and other study
features, as well as information on methods and reporting practices,
and the reported incremental cost-effectiveness ratios. We stand-
ardized incremental cost-effectiveness ratios by converting the
numerator to 2013 US dollars using currency exchange rates and
the consumer price index.Data Analysis
We analyzed the growth and characteristics of published CUAs
through 2012. To characterize changes over time, we divided the
CUAs into three publication time periods: 1990 to 1999, 2000 to
2009, and 2010 to 2012. We chose to present the data by decade
because it provides a convenient demarcation for showing gen-
eral trends and provides sufﬁcient sample size for each category.
We then summarized key features, such as country of study,
study sponsorship, author afﬁliation, disease category, preven-
tion stage, journal of publication, and intervention type by time
period. We also reviewed several methodological and reporting
practices, such as use of discount rates for costs and QALYs,
reporting of economic data alongside clinical trials, performance
of probabilistic sensitivity analyses, and inclusion of cost-
effectiveness acceptability curves. We performed a Cochran-
Armitage trend test to evaluate changes in study features and
methodological quality over time.
We identiﬁed “high-volume” CUA journals (those publishing
>25 CUAs through 2012) and computed the proportion of CUA
articles published by each that were funded by the0
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Fig. 1 – Growth in the number of CUAs. The CEA Registry include
the CEA Registry is from 1976. CEA, cost-effectiveness analysis;pharmaceutical or medical device industry. We also explored
the geographic distribution of CUAs. In particular, we tabulated
the number of CUAs by country and across world regions, on the
basis of the United Nations Geoscheme [10], and across high-,
middle-, and low-income countries using World Bank classiﬁcations
in 2012 [11]. For each of these geographic categories, we also
identiﬁed the most common health conditions studied. Finally, for
each of the three regions (the Americas, Europe, and the Western
Paciﬁc), we analyzed the association between the burden of leading
diseases (disability-adjusted life-years per 100,000 population in
2011) and the number of CUAs published from 2000 to 2011.Results
Growth and Characteristics of CUAs, 1990–2012
The number of CUAs published has risen from 34 per year during
the 1990s to 212 per year during the 2000s and 431 per year from
2010 to 2012 (Fig. 1). Notably, 45% more CUAs were published
during 2012 (n ¼ 538) than during 2011 (n ¼ 372).
The characteristics of published CUAs have shifted over time
(Table 1). Studies from the United States comprise a declining
portion of published English-language CUAs, decreasing from
61% during 1990 to 1999 to 35% during 2010 to 2012 (P o
0.0001). In terms of diseases studied, CUAs have focused most
frequently on cardiovascular diseases (18% of the studies overall),
cancer (15%), and infectious diseases (15%). The most common
interventions addressed by CUAs include pharmaceuticals (47%),
followed by surgeries (13%), screening (12%), and medical proce-
dures (12%). Most CUAs have targeted treatments (65%), followed
by secondary (19%) and primary (16%) prevention.
The proportion of studies sponsored by pharmaceutical and
medical device companies increased from 17% (1990–1999) to 34%
(2010–2012) (P o 0.0001), whereas the proportion of government-
funded studies declined during the period from 40% (1990–1999)
to 35% (2010–12) (P ¼ 0.096). The proportion of studies not
disclosing their funding source declined from 39% (1990–1999)
to 15% (2010–2012) (P o 0.0001). The proportion authored by
individuals afﬁliated with pharmaceutical companies increased
from 6% (1990–1999) to 25% (2010–2012) (P o 0.0001), while the
proportion of studies with authors afﬁliated with private con-
sulting ﬁrms increased from 7% (1990–1999) to 24% (2010–2012)
(P o 0.0001). Most of the studies (88% overall) continue to have at
least one academic author.ar
s 19 CUAs published before 1990. The ﬁrst CUA published in
CUA, cost-utility analysis.
Table 1 – Characteristics and methods.
Characteristic 1990–1999 2000–2009 2010–2012 Overall Trend test (P)
Number of CUAs 339 2120 1294 3753
Country*
United States 61% 41% 35% 40% o0.0001
United Kingdom 8 20 17 18 0.18
Canada 8 7 8 8 0.42
Other† 23 33 41 34 o0.0001
Diseases
Cardiovascular 23% 17% 17% 18% 0.067
Cancer 16 14 18 15 0.023
Infectious 16 15 15 15 0.62
Musculoskeletal/rheumatologic 6 10 9 9 0.40
Other‡ 38 44 41 42 0.69
Intervention*
Pharmaceutical 39% 49% 46% 47% 0.42
Surgical 18 13 12 13 0.01
Screening 12 10 15 12 0.005
Medical procedure 12 12 10 12 0.099
Care delivery 9 13 10 11 0.37
Other§ 25 35 34 34 0.045
Study funder*
Government 40% 37% 35% 37% 0.096
Pharmaceutical/medical device 17 32 34 31 o0.0001
Foundation 14 12 9 11 0.001
Other 5 11 13 11 0.0002
None 1 4 10 6 o0.0001
Not disclosed 39 21 15 20 o0.0001
Author afﬁliation*
Academic 92% 89% 87% 88% 0.002
Health care organization 17 35 38 34 o0.0001
Consultant/contract 7 19 24 20 o0.0001
Pharmaceutical/device industry 6 19 25 20 o0.0001
Government 14 15 17 15 0.023
Other 2 2 2 2 0.54
Prevention stage
Primary 11% 17% 16% 16% 0.24
Secondary 19 19 19 19 0.76
Tertiary 70 64 65 65 0.24
Costs and QALYs discounted
3% 24% 46% 41% 42% 0.021
5% 37 7 8 10 o0.0001
Other 34 45 48 45 o0.0001
None 5 3 3 3 0.26
Economic data collected alongside clinical trial 9 21 17 18 0.25
Performed probabilistic sensitivity analysis 4 50 67 51 o0.0001
Included acceptability curves 0 31 45 33 o0.0001
Note. Trend test performed using the Cochran-Armitage test to calculate P values. Values are in percentages.
CUA, cost-utility analysis; QALY, quality-adjusted life-year.
* Categories are not mutually exclusive.
† Other leading countries include The Netherlands (7% overall), Sweden (5%), Germany (3%), and Italy (2%).
‡ Other diseases include neuropsychiatric and neurological conditions (9% overall) and endocrine conditions (7%). §Other interventions include
health education/behavior (9% overall), medical device (8%), diagnostic (8%), and immunization (7%).
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analyses increased from 4% during the 1990s, to 50% during the
2000s, and 67% between 2010 and 2012 (P o 0.0001). Cost-
effectiveness acceptability curves did not appear in the literature
until the 2000s. During that decade, 31% of the articles included an
acceptability curve, a proportion that increased to 45% for the
period 2010 to 2012 (Po 0.0001). Most studies (97%) have discounted
costs and QALYs. Only 18% of the CUAs have collected economic
data alongside a clinical trial, and the proportion declined from 21%
during the 2000s to 17% during the 2010 to 2012 period.CUAs by Journal and Industry Sponsorship
The number of journals publishing CUAs has increased markedly
—from 58 journals in 2000 to 251 in 2012. The top 10 journals by
CUA volume have changed over time (Table 2). For example, the
Journal of Medical Economics, which ranked ﬁrst by volume in 2012
with 38 CUAs (7.1% of the total in 2012), had published only 9
CUAs in 2009 (2.3% of the total in 2009). Some journals have
persisted in the top 10 (e.g., Pharmacoeconomics, which ranked ﬁrst
in 2000, with 6 CUAs, was ﬁfth in 2012 with 14 CUAs).
Table 2 – Top 10 journals by number of CUAs published.*
Top journals 2000, no. of articles Top journals 2012, no. of articles Top journals overall, 1976–2012, no. of articles
Pharmacoeconomics, 6 J Med Econ, 38 Pharmacoeconomics, 162
Ann Intern Med, 5 Value Health, 22 Value Health, 156
Am J Med, 4 PLoS One, 21 Int J Technol Assess Health Care, 88
Am J Gastroenterol, 3 Clin Ther, 15 Vaccine, 79
JAMA, 3 Pharmacoeconomics, 14 Ann Intern Med, 72
Radiology, 3 Vaccine, 12 J Med Econ, 72
AIDS,† 2 Eur J Health Econ, 9 Curr Med Res Opin, 71
Arthritis Rheum,† 2 Int J Technol Assess Health Care, 9 BMJ, 62
Circulation,† 2 BMJ Open, 8 Clin Ther, 60
Clin Infect Dis,† 2 Clinicoecon Outcomes Res, 8 Eur J Health Econ, 46
CEA, cost-effectiveness analysis; CUA, cost-utility analysis.
* The total number of journals publishing CUAs at present in the CEA Registry is 780. The total number of journals that published CUAs in 2000
was 58, and the total number of journals that published CUAs in 2012 was 251. The complete list is available online at www.cearegistry.org.
† Additional journals with 2 CUAs published in 2000: Int J Radiat Oncol Biol Phys, Int J Technol Assess Health Care, J Clin Oncol, J Gen Intern Med, J Natl
Cancer Inst, J Vasc Surg, and Transfusion.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 7 1 – 2 7 7274The proportion of studies with industry sponsorship varies
considerably across journals (Fig. 2). The CUAs published in some
journals, such as Journal of Medical Economics, Current Medical
Research and Opinion, Clinical Therapeutics, and Applied Health
Economics and Health Policy, are overwhelmingly funded by the
pharmaceutical industry (Fig. 2), whereas CUAs published in
other journals such as JAMA, BMJ,Medical Decision Making, Archives
of Internal Medicine, and Pediatrics are mostly funded by non-
industry sources.Distribution of CUAs by Geographic Focus
Most CUAs have focused on the United States, the United King-
dom, Canada, and countries in Western and Northern Europe
(Table 3). In these countries, cardiovascular disease has been the
most common condition studied (20%, 19%, 16%, and 20%,
respectively). In contrast, CUAs in Africa, Latin America, and0%
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Fig. 2 – High-volume journals (n ¼ 22) that published more than 2
cost-utility analysis.South/West Asia have focused more on infectious diseases (83%,
41%, and 35%, respectively). The vast majority of published CUAs
pertain to high-income countries (Fig. 3), although the number
focused on middle-income countries increased from single-digit
numbers in the early 2000s to more than 40 per year in 2012. Very
few published CUAs in English-language journals have focused
on low-income countries.
Finally, we examined the association between burden of
disease (disability-adjusted life-years per 100,000 members of
the population in 2011) and the number of CUAs published from
2000 to 2011 for the six most common World Health Organiza-
tion classiﬁcation disease categories for the European,
Americas, and Western Paciﬁc regions (Fig. 4) [12,13]. In Europe
and the Americas, cardiovascular disease not only imposes
a high disease burden but is also the focus of a large number
of CUAs. In Europe, the number of CUAs focused on muscu-
loskeletal disease is relatively large compared with theA
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Industry sponsored CUAs
5 CUAs through 2012, ranked by industry sponsorship. CUA,
Table 3 – Geographic distribution of CUAs (top two disease categories by region).
Geographic
region
No. of
articles
Cancer Cardiovascular Infectious Musculoskeletal/
rheumatologic
Neuropsychiatric/
neurological
United States 1531 20% 18%
United Kingdom 675 19% 13%
Canada 291 19% 15%
Western Europe* 646 15% 16%
Northern Europe
(minus UK)*
308 20% 18%
Eastern Europe* 46 24% 20% 20%
Africa* 29 7% 7% 83%
Latin America* 37 22% 41%
East Asia 132 28% 20%
Southeast Asia/
Oceania*
139 21% 9% 21%
South/West Asia* 23 17% 35%
Note. Percentages for the top two disease categories are presented for each region or country, with the top disease in bolded font. For ties, the
two tied categories are reported with the same percentage.
CUA, cost-utility analysis.
* Several regions were combined or changed from the original United Nations Geoscheme [8]: All African regions were combined. The Latin
America region includes Caribbean, Central America, and South America. The South/West Asia region includes Central, Southern, and
Western Asia; South-Eastern Asia and Oceania; Latvia and Lithuania were included in Eastern Europe (instead of Northern Europe). Countries
from Southern Europe were included in either Eastern or Western Europe: Greece, Slovenia, and Serbia were included in Eastern Europe; Italy,
Spain, and Portugal were included in Western Europe.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 7 1 – 2 7 7 275burden associated with this disease category. For the Western
Paciﬁc region, the number of CUAs focused on cancer and
infectious disease is large relative to the corresponding burdens2000 2001 2002 2003 2004 2005 2006
High 84 80 112 142 174 221 215
Middle 1 3 3 2 2 3 11
Low 1 0 0 0 0 0 0
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Fig. 3 – Distribution of CUAs by income of country (2000–2012),
analysis. High-income countries: http://data.worldbank.org/inco
worldbank.org/income-level/MIC; low-income countries: http://dfor these disease categories. However, in all regions, few
CUAs have focused on injuries relative to the corresponding
burden.2007 2008 2009 2010 2011 2012
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Low
using 2012 World Bank income groups [9]. CUA, cost-utility
me-level/HIC; middle-income countries: http://data.
ata.worldbank.org/income-level/LIC.
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Fig. 4 – Burden of disease (2011) and CUAs (2000–2011) by WHO region [10,11], for most common disease categories from 2011.
The Americas region includes countries of Latin America including Central and South America, the Caribbean, and Northern
America. The Western Paciﬁc Region includes countries of Eastern Asia (China, Japan, Malaysia, South Korea, Vietnam, etc.),
Oceania (Australia and New Zealand), and Paciﬁc Islands (Fiji, French Polynesia, Guam, Micronesia, Palau, etc.). CUA, cost-
utility analysis; DALY, disability-adjusted life-year; WHO, World Health Organization.
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Our review reveals considerable growth in the cost-utility liter-
ature during recent years and some shift in the types of analyses
published. To put this literature’s growth into perspective, two-
thirds of all CUAs ever published through 2012 were published
after January 1, 2006. The trend suggests growing interest in CUA
on the part of researchers, funders, and journal editors, and
presumably on the part of end users as well.
Interestingly, the publication of CUAs seemed to plateau
during the period 2008 to 2011 at roughly 350 studies per year.
Although it is not clear why the publication rate leveled off, it is
possible that the pause was driven by criticisms of the QALY in
some quarters during this general time period [14,15]. The late
2000s saw some payers backing away from CUAs. For example,
the United Kingdom proposed that the National Institute forHealth and Care Excellence would not use such cost-per-QALY
information to make yes or no recommendations and instead
move to a value-based pricing scheme [16]. In Germany, the
Institute for Quality and Efﬁciency in Health Care rejected the
cost-per-QALY model on ethical and methodological grounds,
and some countries (e.g., France, Spain, and Italy) have shied
away from using QALYs to inform reimbursement decisions
[14,15,17]. Alternatively, the pause may have reﬂected economic
constraints in funding studies in the wake of the 2008 ﬁnancial
crisis, though lags in the time between funding decisions and
publication make this seem less likely.
The 2012 jump to 540 CUAs published (and initial results
indicating that this number was even greater in 2013) suggests
that CUAs have durable and even growing appeal. In 2012, some
journals (e.g., the Journal of Medical Economics, PLoS ONE, Clinical
Therapeutics, Pharmacoeconomics, and BMJ Open) markedly increased
the number of CUAs published. For example, the Journal of Medical
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 2 7 1 – 2 7 7 277Economics and PLoS One published 38 and 21 CUAs, respectively,
during 2012, compared with 11 each during 2011. Moreover, the
number of journals publishing CUAs for the ﬁrst time grew in 2012;
that year, there were 60 such journals, including the Bulletin of the
World Health Organization, the Journal of the American Medical
Informatics Association, and the Journal of Cancer.
Our analysis also shows that the origin of the English-language
CUA literature is also changing, with more CUAs emanating from
non-Western countries (though the majority still comes from the
United States, the United Kingdom, Canada, and Western Europe).
The data reveal a paradox of sorts in that the United States
continues to be the focus of a large share of the CUAs published,
despite the fact that CEA rarely seems to play an explicit role in
reimbursement decisions in the United States, and, in fact, has been
prohibited as a consideration for the Medicare program [18]. To be
sure, the share of US-focused published CUAs has declined in
recent years from 61% in the 1990s to just 35% in the 2010 to 2012
period, whereas the share focusing on countries that actively use
such information has increased (e.g., the share of UK-focused CUAs
increased from 8% to 17% during this time). The ongoing publica-
tion of many US-focused CUAs (over 450 from 2010 to 2012),
however, suggests that CUAs may in fact play an important indirect
role in such decisions. Their publication may inﬂuence the actions
and policies of US thought leaders, clinical guideline developers,
and perhaps payers themselves, though not in an explicit manner.
Our study also reveals less focus of CUAs during recent years
on cardiovascular disease and that the ﬁeld continues to devote
much of its attention to pharmaceuticals. Furthermore, the
proportion of CUAs funded by drug companies continues to rise.
More studies are being coauthored by investigators working for
private consulting ﬁrms. In terms of methods and reporting,
many more studies are including probabilistic sensitivity analysis
and acceptability curves, and more publications are disclosing
their source of funding. Finally, comparisons of disease burden
and the number of CUAs published by region show that a limited
number of CUAs have targeted interventions to prevent or treat
injuries, despite its high burden across all regions.
The number of published CUAs continues to grow, suggesting a
healthy state of the ﬁeld. The growth in interest among non-Western
countries has been strong, although the absolute number of studies
from these countries remains relatively small. This study also high-
lights the disproportionate focus on pharmaceuticals and the lack of
attention for certain conditions, such as injury prevention.
Source of ﬁnancial support: This study was funded by internal
sources at the Center for the Evaluation of Value and Risk in
Health at Tufts Medical Center. The center receives funding from
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